4.94
Bio Green Med Solution Inc stock is traded at $4.94, with a volume of 15,016.
It is up +1.23% in the last 24 hours and up +0.00% over the past month.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.
See More
Previous Close:
$4.88
Open:
$4.75
24h Volume:
15,016
Relative Volume:
1.71
Market Cap:
$11.06M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+4.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Bio Green Med Solution Inc Stock (BGMS) Company Profile
Name
Bio Green Med Solution Inc
Sector
Industry
Phone
908-517-7330
Address
200 CONNELL DRIVE, BERKELEY HEIGHTS
Compare BGMS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BGMS
Bio Green Med Solution Inc
|
4.94 | 14.34M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Bio Green Med Solution Inc Stock (BGMS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-18-22 | Resumed | Oppenheimer | Outperform |
Apr-27-20 | Resumed | ROTH Capital | Buy |
Sep-07-18 | Initiated | Ladenburg Thalmann | Buy |
Oct-16-15 | Initiated | H.C. Wainwright | Buy |
Feb-04-10 | Initiated | Roth Capital | Buy |
Oct-28-09 | Initiated | Merriman | Buy |
Aug-12-08 | Initiated | Piper Jaffray | Buy |
Mar-12-08 | Reiterated | Cantor Fitzgerald | Buy |
Mar-12-08 | Reiterated | Collins Stewart | Buy |
Mar-12-08 | Reiterated | Needham & Co | Buy |
Nov-27-07 | Reiterated | Cantor Fitzgerald | Buy |
Aug-10-07 | Reiterated | Cantor Fitzgerald | Buy |
Jun-04-07 | Reiterated | Needham & Co | Buy |
Apr-23-07 | Initiated | Lazard Capital | Buy |
Apr-10-07 | Initiated | Cantor Fitzgerald | Buy |
View All
Bio Green Med Solution Inc Stock (BGMS) Latest News
Biodexa Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:BDRX - Benzinga
Bio Green Med Solution Appoints New Independent Director - TipRanks
Cyclacel Pharmaceuticals: Recent Acquisition Completed - MSN
Bio Green Med Solution Faces Nasdaq Delisting Notice - TipRanks
BlackRock® Canada Announces Product Changes - The Manila Times
Inception Growth Acquisition Limited Announces Additional Contribution to Trust Account to Extend Business Combination Period - The Manila Times
Bio Green Med Solution announces closing of strategic acquisition of Fitters Sdn. Bhd. - MarketScreener
Bio Green Med Solution, Inc. Completes Acquisition of Fitters Sdn. Bhd. to Diversify Business Portfolio - Quiver Quantitative
Major Shareholder Cashes Out Big on Cyclacel Pharmaceuticals! - TipRanks
Cyclacel Pharmaceuticals Approves Key Shareholder Proposals - TipRanks
Cyclacel Pharmaceuticals shareholders approve share issuance and name change - Investing.com
Cyclacel Pharmaceuticals : Initial Statement of Beneficial Ownership (Form 3) - MarketScreener
Big Moves And Bigger Questions For Biotech And Tech Stocks - Finimize
Cyclacel Pharmaceuticals to Implement 1-for-15 Reverse Stock Split; Shares Fall - MarketScreener
Cyclacel Pharmaceuticals, Inc. announced that it has received $3 million in funding - MarketScreener
CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT - MarketScreener
Fitters swaps fire safety arm for 19.99% stake in Nasdaq biotech firm - The Malaysian Reserve
Wacker Buys Manufacturing Assets and Know-how of Bio Med Sciences - CHEManager
Cyclacel Pharmaceuticals, Inc. Announces Chief Executive Officer Changes - MarketScreener
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - MarketScreener
Roth MKM Downgrades Cyclacel Pharmaceuticals(CYCC.US) to Hold Rating - 富途牛牛
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - MarketScreener
WACKER Positions itself as Solution Provider for Silicone-Coated Healthcare Products with New Acquisition - PR Newswire
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results - MarketScreener
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO and Investor Conference - MarketScreener
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer - MarketScreener
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - MarketScreener
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit - MarketScreener
Alaunos Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TCRT - Benzinga
Waste biorefinery towards a sustainable circular bioeconomy: a solution to global issues - Biotechnology for Biofuels and Bioproducts
Cyclacel Pharmaceuticals Announces Management Changes - MarketScreener
Psyence Biomedical Stock Price, Quotes and Forecasts | NASDAQ:PBM - Benzinga
Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures - MarketScreener
Cyclacel Pharmaceuticals to Present at the Noble Capital Markets Investor Conference - MarketScreener
Bio Green Med Solution Inc Stock (BGMS) Financials Data
There is no financial data for Bio Green Med Solution Inc (BGMS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):